U.S. Markets closed


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
23.70+0.95 (+4.18%)
At close: 12:13PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.75
BidN/A x N/A
AskN/A x N/A
Day's Range22.75 - 22.75
52 Week Range15.75 - 22.75
Avg. Volume506
Market CapN/A
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock

    Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock

    Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% royalty of the annual net sales. The acquisition will include late clinical-stage drug Abivertinib, AC0058, AC0939, and ACEA's extensive proprietary library of small molecules (over 1,000,000 compounds). Lead candidate abivertinib is a small molecule tyrosine kinase inhibitor that selectively targets both a mutant form of the epidermal growth factor receptor and Bruton's tyrosine kinase. It is currently being studied as a Phase 2 treatment for COVID-19-induced respiratory compromise in the U.S. and Brazil. AC0058 a BTK inhibitor, is currently in a Phase 1b trial for Lupus patients in the U.S. The acquisition will also include ACEA's facility located in Quzhou, China, on a 23-acre campus with five buildings. The facility currently can manufacture up to 5,000 kg/year of APIs and 50 million capsules of the final drug product. The merger is expected to close in the second quarter of 2021. Price Action: SRNE shares gained 1.5% at $8.13 in market trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For MigraineInvitae Accelerates Personalized Oncology Testing With Genosity Acquisition© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • A bitcoin ETF could finally come this year: Mike Novogratz
    Yahoo Finance

    A bitcoin ETF could finally come this year: Mike Novogratz

    Long-considered the Holy Grail of retail crypto investment, a U.S.-listed bitcoin ETF may be on the horizon.